ArticleFrontiers in oncology2026
Effects of trimodal prehabilitation on quality of life and negative emotions in patients with advanced triple-negative breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the effectiveness of a four-week trimodal prehabilitation program in enhancing the quality of life, clinical symptoms, and negative emotions of stage IV triple-negative breast cancer patients who are undergoing first-line systemic therapy. Optimize comprehensive care management for advanced cancer patients by providing evidence-based guidance. Methods: Ninety-seven patients with stage IV triple-negative breast cancer at Xuzhou Central Hospital were selected from January 2024 to June 2025, and categorized into an observation group (49 cases) and a control group (48 cases). The control group underwent standard anti-tumor treatment and routine care, whereas the observation group engaged in a 4-week trimodal prehabilitation intervention in conjunction with standard treatment. The quality of life of patients, along with cancer-related fatigue, pain, anxiety, and depression, was evaluated using the Functional Assessment of Cancer Therapy-Breast (FACT-B), the Revised Piper Fatigue Scale (PFS-R), the Numerical Rating Scale (NRS), the Hamilton Anxiety Rating Scale (HAMA), and the Hamilton Depression Rating Scale (HAMD) prior to and following the intervention. Patients in two groups were followed up after the completion of treatment to record their progression-free survival (PFS). Results: Following the intervention, the observation group had significantly higher scores on the FACT-B scale (112.16 ± 4.67) than the control group (P < 0.001). They experienced considerably less cancer-related fatigue (5.33 ± 0.72) than the control group (P < 0.001), but there was no significant difference in pain scores between the two groups (P > 0.05). The observation group demonstrated considerably reduced levels of anxiety (13.14 ± 4.14) and depression (10.65 ± 3.48) compared to the control group (P < 0.001). In this trial, we preliminarily observed a longer PFS in the observation group compared with the control group (298.00 vs 235.00, P = 0.0237), along with a favorable safety profile. Conclusion: Among patients with stage IV triple-negative breast cancer receiving first-line systemic therapy, a 4-week trimodal prehabilitation intervention was associated with significantly improved quality of life, reduced cancer-related fatigue, anxiety, and depression. It is possible that the improvement in quality of life may translate into a survival benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.